

WILL HE BE WEARING CHILDREN'S CLOTHES WHEN HE'S A 'GROWN-UP'?

Prescribing Information

Somatnorm 4IU

Presentation A vial of sterile lyophilised powder of somatrem corresponding to 4 IU of human somatotropin (also containing aminoacetic acid and sodium phosphate as stabilisers) and supplied with a 2ml ampoule of water for injections for use in the reconstitution of the injection.

Uses The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. The diagnosis should be verified by appropriate investigations of pituitary function by a specialist medical practitioner.

Dosage and Administration
Route of administration: By intramuscular or subcutaneous injection. The dosage should be calculated according to the patient's body weight. Generally a dose of 0.5 IU/kg body weight per week is recommended. This weekly dose should be divided into 2 or 3 intramuscular or 6 or 7 subcutaneous injections. If given subcutaneously injection sites should be rotated to prevent lipodystrophy.

Contra-indications Diabetes mellitus.

Warnings Only patients with unfused epiphyses should be treated.

Precautions Patients treated with Somatnorm should be regularly assessed by a specialist in child growth.

Side-effects Clinical experience with Somatnorm is limited and recipients may develop antibody to growth hormone and *E. coli* protein. However, as with pituitary derived hormone, only in very rare instances has growth retardation occurred. No other adverse reactions have been noted.

Package Quantities Combined package containing one vial of somatrem 4IU and one ampoule of 2 ml water for injections.

Price NHS Price £30.50

Further Information Somatrem is the British Approved Name for 'methionyl human somatotropin'.
Product Licence Number 0022-0360.

KABIVITRUM LTD: KabiVitrum House, Riverside Way, Uxbridge, Middlesex, UB8 2YF.

Product Authorisation Number 187 281

EIRE: KabiVitrum, Cahill May Roberts Ltd, PO Box 1090, Chapelizod, Dublin 20.



Somatnorm® (somatrem)

is successfully changing the outlook for this child and thousands like him suffering from short stature caused by growth hormone deficiency (GHD).

With early diagnosis and treatment, GHD children can achieve a normal adult height.

For the past two decades, KabiVitrum has pioneered growth hormone research.

The introduction of Somatnorm ensures that, for the first time, sufficient growth hormone is available to treat all GHD children.

HE WANTS TO GROW. KabiVitrum  CAN HELP HIM.



What would you feed her if

The Challenge

This question is one of the biggest challenges in neonatology today. Preterm infants may have a five fold increase in body weight and corresponding increase in caloric requirements. Advances over the last few years have made important contributions to the management of these infants' nutritional needs.

References

1. Committee on Nutrition of the preterm infant. European Society of Paediatric Gastroenterology and Nutrition. Nutrition and feeding of preterm infants. Oxford: Blackwell, 1987.
2. ESPGAN Committee on Nutrition of the Preterm Infant. *Acta Paediatr Scand*. 1987 Suppl 336: 1-14.
3. Salle, B., Putet G., Service de Neonatologie de L'Hopital Edouard Herriot, Lyon, France. Senterre J., Rigo, J., Neonatologie de L'Hopital Universitaire de Baviere, Liege, Belgium.

she were born premature?

ESPGAN - Sets New Standards in Preterm Nutrition

A comprehensive review¹ and Guidelines² on nutrition and feeding of preterm infants have recently been published by the European Society of Paediatric Gastroenterology and Nutrition (ESPGAN).

New Milupa Prematil – Meets ESPGAN Guidelines for Preterm Formulae

Developed to incorporate recent advances


Milupa Prematil meets the ESPGAN Guidelines and translates them into action.

New Milupa Prematil – Proven Performance in clinical trials^{3,4}

- ★ High fat absorption (87%) ensures energy retention and enhances protein utilization.³
- ★ Excellent protein utilization (90%) promotes growth without metabolic overload.³
- ★ Good tolerance and nutritional balance ensures supplementation is rarely required.^{4†}

NEW milupa
Prematil®

From Milupa Prematil to Aptamil® an assured path to normal formula feeding.



PRESCRIBING INFORMATION

HUMAN VELOSULIN® ▼ (Neutral Insulin Injection, human insulin (emp)), HUMAN INSULATARD® ▼ (Isophane Insulin Injection (NPH), human insulin (emp)), HUMAN MIXTARD® 30/70 ▼ (Neutral Suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection (NPH), human insulin (emp)), HUMAN INITARD® 50/50 ▼ (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection (NPH), human insulin (emp)). **Presentation** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10 ml. vials containing 100 iu/ml. To aid identification the metal sealing rings of the vials have tactile marks as follows: Human Velosulin – one mark; Human Insulatard – two marks; Human Mixtard 30/70 – three marks; Human Initard 50/50 – four marks. The vials are fitted with tamper-evident caps. **Uses** The treatment of insulin-requiring diabetes. **Dosage and Administration** The dosage of insulin is determined by the physician according to the needs of the patient. Human Velosulin may be given by s.c., i.m., or i.v. injection. Human Insulatard, Human Mixtard 30/70 and Human Initard 50/50 should be re-suspended by inverting the vial several times before being given by s.c. or i.m. injection (they must not be given intravenously). Intermixing does not affect the characteristics of any of these insulins. **Use in pregnancy:** Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Use in the elderly:** Insulin may have a more prolonged action due to reduced clearance rates. **Contra-indications warnings etc. Contra-indications:** Hypoglycaemia. **Precautions:** Patients transferring from other insulins may require a dosage adjustment. Concomitant therapy with thyroxine, corticosteroids, oral contraceptives, diuretics, beta blockers and M.A.O.I.s may affect insulin requirements. **Side and Adverse Effects:** Hypoglycaemia. Local reactions, lipodystrophy and hypersensitivity reactions are rarely reported with human insulins. **Pharmaceutical Precautions** be used. **Legal Category P. Package Quantities** 10 ml. glass vials. **Basic NHS Price** Human Insulatard 3132/0034; Human Mixtard 30/70 3132/0037; Human Initard 50/50 Insulatard 0003/0212; Human Mixtard 30/70 0003/0213; Human Initard 50/50 0003/0214. House, Garland Court, Garland Road, East Grinstead, West Sussex RH19 1DN. Foundation Ltd, Crewe Hall, Crewe, Cheshire CW1 1UB. Tel: Crewe (0270) 583151.



Store between 2-8°C, protected from sunlight. Insulin which has been frozen should not be used. **Product Licence Numbers** NORDISK-UK: Human Velosulin 3132/0031; 3132/0040, THE WELLCOME FOUNDATION LTD: Human Velosulin 0003/0211; Human Further information is available on request from either: Nordisk-UK, Nordisk Tel: East Grinstead (0342) 410373, or Wellcome Medical Division, The Wellcome Reference 1. Heine R.J, et al, Diabetologia, 1984; 27; 558-562. ®Registered Trade Mark




HUMAN VELOSULIN®
Human neutral soluble insulin (emp)

HUMAN INSULATARD®
Human isophane (NPH) insulin (emp)

Quick and intermediate acting insulins developed to be compatible.
No interaction when mixed.!
Predictable effect in individually titrated regimens.

One revolution leads to another . . .



The extraordinary technical developments in molecular biology over the past few years, and the equally rapid advances in understanding of cell biology, will almost certainly result in far reaching changes in medical research and practice. In this collection of articles experts in molecular and cell biology provide the background information to give clinicians an insight into the way in which the medical sciences may be moving over the next few years and into the exciting possibilities opening up for the treatment of genetic disorders, cancer, and the common illnesses of Western society such as degenerative vascular disease and diabetes.

Price: Inland £5.95; Abroad £7.50; USA \$12.00
BMA members: Inland £5.45; Abroad £7.00; USA \$11.00
including postage, by air abroad

Payment must be enclosed with order.

Order from BRITISH MEDICAL JOURNAL, PO Box 295, London WC1H 9TE
or any leading medical bookseller

NEW BOOKS FROM BUTTERWORTHS

PAEDIATRIC DATA INTERPRETATION

John Walter, MRCP, DCH

Clinical Research Fellow, Institute of Child Health, University of London, UK

Simon Lenton, MRCP, DRCOG

Lecturer in Community Child Health and Honorary Senior Registrar in Paediatrics, Department of Child Health, Southampton General Hospital, UK

Cynthia M Gabriel, FRCP, DCH

Consultant Paediatrician, St Albans City Hospital and Queen Elizabeth II Hospital, Welwyn Garden City, Hertfordshire, UK

- ★ **Contains over 130 questions based on the current format of the paediatric MRCP examination**
- ★ **Text well illustrated throughout**
- ★ **Authors well known in the field**

October 1987 200 pages 210 × 130 mm Softcover Illustrated 0 407 00425 4 £7.95

LIVER DISORDERS IN CHILDHOOD Second Edition

Alex P Mowat, MB ChB, FRCP, DObst, RCOG

Consultant Paediatrician and Paediatric Hepatologist, King's College Hospital and King's College School of Medicine and Dentistry, London, UK

- ★ **The standard work on paediatric liver disorders**
- ★ **New edition completely revised and updated**
- ★ **Increased in size**
- ★ **Author established in the field**

July 1987 416 pages 234 × 165 mm Hardcover Illustrated 0 407 00163 8 £45.00

SCOTT-BROWN'S OTOLARYNGOLOGY Fifth Edition

VOLUME 6 PAEDIATRIC OTOLARYNGOLOGY

Edited by **N G Evans**, MBBS, DLO, FRCS

Consultant Ear, Nose and Throat Surgeon, The Hospital for Sick Children, Great Ormond Street and St Thomas' Hospital, London, UK

- ★ **Entirely new volume in the Scott-Brown series**
- ★ **First complete British paediatric reference for 30 years**
- ★ **Beautifully illustrated**
- ★ **Covers congenital and acquired conditions, paediatric audiology and disorders of speech and language**

November 1987 384 pages 246 × 189 mm Hardcover Illustrated 0 407 00516 1 £65.00

Rob and Smith's Operative Surgery PAEDIATRIC SURGERY Fourth Edition

Edited by **Lewis Spitz**, PhD, FRCS

Nuffield Professor of Paediatric Surgery, Institute of Child Health, London, UK

H Homewood Nixon, FRCS, FAPP(Hon)

Consultant Paediatric Surgeon, The Hospital for Sick Children, Great Ormond Street, London, UK

- ★ **Substantially revised and expanded**
- ★ **Ten completely new chapters**
- ★ **Many new contributors**
- ★ **Lavish illustration with most drawn afresh**
- ★ **Indispensable companion to paediatric surgical practice**

September 1988 600 pages approx 276 × 219 mm Hardcover Illustrated 0 407 00666 4 £120.00 approx

Please order these titles from your usual bookseller – or in case of difficulty from Butterworths at the address below.



Butterworths
meeting professional needs

